References:
1. Holl-Ulrich, K., [Vasculitis: New nomenclature of the Chapel Hill consensus conference 2012]. Z Rheumatol, 2014. 73 (9): p. 823-33; quiz 834-5.
2. Yazici, H., et al., Behçet syndrome: a contemporary view.Nature Reviews Rheumatology, 2018. 14 (2): p. 107-119.
3. Davatchi, F., et al., The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. Journal of the European Academy of Dermatology and Venereology, 2014. 28 (3): p. 338-347.
4. Yazici, H., The place of Behcet’s syndrome among the autoimmune diseases. Int Rev Immunol, 1997. 14 (1): p. 1-10.
5. Gul, A., Behcet’s disease as an autoinflammatory disorder.Curr Drug Targets Inflamm Allergy, 2005. 4 (1): p. 81-3.
6. Franks, W.A., et al., Cytokines in human intraocular inflammation. Curr Eye Res, 1992. 11 Suppl : p. 187-91.
7. Bouomrani S, T.S., Guermazi M, Regaïeg N, Thyroid Involvement In Behçet’s Disease. Symbiosis, 2019(Int J Thyro Disord Ther 1 (1): 1-7).
8. Lockwood, C.M., et al., Remission induction in Behcet’s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.Rheumatology (Oxford), 2003. 42 (12): p. 1539-44.
9. Colak, R., et al., A comparison between the effects of low (1 ug) and standard dose (250 ug) ACTH stimulation tests on adrenal cortex functions with Behcet’s disease. Journal of the European Academy of Dermatology and Venereology, 2006. 20 (6): p. 721-725.
10. Husebye, E.S., M.S. Anderson, and O. Kampe, Autoimmune Polyendocrine Syndromes. N Engl J Med, 2018. 378 (12): p. 1132-1141.
Figure legends:
Figure 1 shows oral hyperpigmentation (orange arrows).